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Background: Breast cancer has a low incidence in Africa compared with other continents.  
Of breast cancer reported in Africa, middle and eastern Africa is reported with the lowest 
incidence.  In general, there is a paucity of information about breast cancer in Africa.  
Breast cancer evaluation and treatment is plagued with inadequate resource and screening 
facility throughout sub-Saharan Africa. Therefore, it is difficult to adequately assess 
incidence or prevalence without appropriate cancer or death registries.  To our knowledge, 
no data exists for breast cancer treated in rural Kenya.                      
Methods: Review of all surgical pathology reports was performed from January 31, 1993 
to August 31, 2007 at Tenwek Hospital, a 300 bed referral center located in Bomet, Kenya.  
Records were searched for any breast specimen or specimen related to breast disease such 
as metastatic breast disease.                       
Results: For the studied period, a total of 118 breast cancers were identified from 
pathology report records. Men accounted for 13 (11.02%) of all breast cancers. The 
average age for men was  69 years (std 10.6).  The average age of women (n=105) was 51.2 
years (std 15.6). The difference between the mean ages among men and women was 
statistically significant (p=0.000195).  Grades were listed for only 55 of 118 
specimens. Grade 3 was recorded in 61.8% (34/55).  Women, aged 50 years or less, 
comprised 59.3% of all women recorded ages. In females, Grade 1 occurred in 7.1%, 
Grade 2 in 39.3%, and Grade 3 in 53.6%.  Average age for Grade 1 histology is 37.5 years 
(std 2.1), Grade 2 average was 38.3 years (std 5.9) and Grade 3 average age was 40.8 years 
(std 5.7). The majority of males had IDC (12/13) with one case of NHL and melanoma of 
the breast.   
Introduction  
reast cancer has a low incidence in 
Africa compared with other continents.  
Of breast cancer reported in Africa, 
middle and eastern Africa is reported with 
the lowest incidence.  Paradoxically, the 
ratio of mortality to incidence is among the 
highest in the world1. Some areas of Africa 
have seen an increase in incidence in recent 
years possibly being related to increased 
screening and awareness2.  Typical patterns 
of breast cancer in Africa include a low 
incidence, high mortality, presentation at 
advanced stage and limited access to health 
care3. Social barriers exist such as social 
taboo and stigma of the disease.  Data from 
North America shows a difference in breast 
cancer epidemiology, survival and histology 
between those of European and African 
descent4. These differences are also similar 
to the differences described above 
comparing what is known of breast disease 
in Africa and other continents.  In general, 
there is a paucity of information about 
breast cancer in Africa.  Breast cancer 
evaluation and treatment is plagued with 
inadequate resource and screening facility 
throughout sub-Saharan Africa. Therefore, it 
is difficult to adequately assess incidence or 
prevalence without appropriate cancer or 
death registries.  To our knowledge, no data 
exists for breast cancer treated in rural 
Kenya.  Several series describing breast 
cancer treated in Nairobi have been reported 
as well as a recent cancer registry based in 
Nairobi5-9. A small series has been reporting 
from neighboring Tanzania12.  Little is 
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known of the natural history, demographics, 
incidence and variations of breast cancer in 
rural Kenya.  We examined breast disease 
treated at a rural hospital in western Kenya.  
Knowledge of breast cancer in this area 
should provide insight into disease pattern 
and guidance for public health efforts to 
focus screening, public awareness and 
treatment centers where they are needed 
most.  An increased understanding of breast 
disease in Africa is needed to contribute to 
the growing literature describing different 
tumor biology among those of African 
descent.      
Patients and Methods  
 Review of all surgical pathology reports 
was performed from January 31, 1993 to 
August 31, 2007 at Tenwek Hospital, a 300 
bed referral center located in Bomet, 
Kenya.  Records were searched for any 
breast specimen or specimen related to 
breast disease such as metastatic breast 
disease.    Data is reported in descriptive 
terms and is limited solely to pathology 
records.  Review of patient medical records 
is limited due to a number of outpatient 
records being discarded after a patient dies.  
Risk factors, clinical and pathologic stage, 
survival outcome, and co-morbidities were 
often not able to be determined.  Data for 
hormone receptor status was also 
unavailable because this service is not 
available at our institution.  It is possible 
that some of these patients were referred to 
Nairobi Hospital for this analysis, but this 
information is not available.  Analysis and 
comparison of means between sub-groups 
was determined with Student’s T-test and 
variance analyzed with Fischer exact test.  A 
value of p<0.05 was interpreted as 
significant.  
Results  
For the studied period, a total of 118 breast 
cancers were identified by review of 
pathology report records.  Of these 118, age 
was reported in 100 with a mean age of 52.9 
years and standard deviation (std) 16.04.  
Men comprised 11.02% of all breast cancers 
(n=13) with an average age of 69 years (std 
10.6).  The average age of women (n=105) 
was 51.2 years (std 15.6). Age was not 
recorded in 15 cases. The difference 
between the mean ages among men and 
women was statistically significant 
(p=0.000195).  During this period, an 
increased patient volume at the hospital as 
well as expansion of facilities were 
associated with more breast lesions being 
treated (Figure 3).  Grades were listed for 55 
of 118 specimens (Table 3).  Three other 
grades were reported with a high grade 
sarcoma, high grade DCIS and one grade 
undetermined.  Of the 55, Grade 1 was 7.3% 
(4/55), Grade 2 was 30.9% (17/55), and 
Grade 3 was 61.8% (34/55).  Grade 1 was 
25% male with mean age of 57 years (std 
22.7).  Grade 2 was 23.5% male with mean 
age of 46.5 years (std 13.7) with age not 
reported in 2 cases.  Grade 3 was 5.6% male 
with mean age of 53.9 years (std 17.4) with 
ages not reported in 6 cases.   
Age 50 years or less was specified as a 
surrogate marker for pre-menopausal state.  
All women aged 50 years or less were 
analyzed.  This age group comprised 55 of 
100 ages reported.  Of the 100 ages 
reported, 10 in this group were men and one 
of these men was 50 years of age.  Thus, 
women, aged 50 years or less, comprised 
59.3% (54/91) of all women with reported 
ages.  Of breast cancers in those aged 50 or 
less, 98.2% were women with a mean age of 
40.3 years (std 6.6) and 50/55 were IDC.  
The other cancers were infiltrating lobular 
cancer (n=3) and sarcoma (n=2).  Grades 
were reported for 28 of these 55 IDC.  
Grade 1 occurred in 7.1%, Grade 2 in 
39.3%, and Grade 3 in 53.6%.  Average age 
for Grade 1 histology is 37.5 years (std 2.1), 
Grade 2 average was 38.3 years (std 5.9) 
and Grade 3 average age was 40.8 years (std 
5.7).  Male breast cancer comprised 11.02% 
with a mean age of 68.5 years (std=10.6). 
The majority had IDC (12/13) with one case 
of NHL and melanoma of the breast.  
Grades were reported in 8 cases with Grade 
1, Grade 2, and Grade 3 having 1 (12.5%), 4 
(50%) and 3 (37.5%), respectively.   
Histology types were classified and are 
listed in Table 1.  IDC comprised 89.8% 
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(n=106), ILC 3.4% (n=4), Sarcoma 3.4% 
(n=4), DCIS 1.7% (n=2) and not otherwise 
specified (NOS) 1.7% (n=2).  Of IDC 
histology, average age was 53.1 years (std 
15.9) with men being 11.4%.  Two subtypes 
occurred of IDC with medullary being 5.6% 
(n=6) and tubular being 1.9%.  Medullary 
subtype had average age of 53 years (std 
15.6).  Tubular subtype had average age 52 
years (std 21.2).  Three cases of IDC 
occurred with DCIS, one with inflammatory 
cancer and one with paget’s disease.  The 
three cases of DCIS are listed in Table 1 
with the two cases that occurred without 
additional findings.  ILC occurred in 3.4% 
with average age of 47 years (std 17.4).  
Sarcoma occurred in 3.4% with average age 
of 43.7 years (std 25.6).  DCIS occurred in 
1.7% with average age 47.6 years (std 17).  
NOS occurred in 1.75 with average age 56.6 
years (std 7.8) (Figure 1).  
 .   
                                
Figure 1. Breast Cancer diagnosed at Tenwek Hospital 1993 to August 2007. 
IDC = infiltrating ductal carcinoma, DCIS = ductal carcinoma in-situ.  ILC = infiltrating lobular carcinoma,           
NOS = not otherwise specified.                                                                                              
                                                 
Figure 2. Mean age at diagnosis of breast lesions treated at Tenwek Hospital. 
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Figure 3. Trend in breast lesions treated at Tenwek Hospital from 1993 to August 2007.    
Table 1. Benign cancer diagnosed at Tenwek Hospital 1993-8/2007.  One hundred twenty-one 
breast cancers diagnosed in 118 patients for the time of 1993 to August 2007.   
 
Std dev = standard deviation, NR = not reported, D.C.I.S = ductal carcinoma in-situ,                                           
NOS = not otherwise specified. 
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Table 2. Benign breast lesions diagnosed at Tenwek Hospital 1993-8/2007.  
 
NR = not reported,           Std dev = standard deviation,                                                                           
N = number,        L.C.I.S. = lobular carcinoma in-situ. 
Table 3. Breast cancer Grades reported for Infiltrating Ductal Carcinoma treated at Tenwek 
Hospital from 1993 to August 2007.   
 
Grade was reported in 55/118 breast cancers treated at Tenwek hospital from 1993 to August 
2007.  Fifty-five diagnoses of IDC occurred in women age 50 or less.  This age was used a 
surrogate marker for pre-menopausal state.  Grades were reported in 28 or these 55.  The 
percentage of these grades in the pre-menopausal population is listed above in the 
premenopausal breast disease column.      
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 Stage was poorly defined based solely on 
review of pathology reports.  When the 
patients died, their records were relocated 
from the record room at this institution.  
When records were found, documentation of 
stage (clinical or pathologic) was 
inadequate.  Minimum stage was 
determined based strictly on the pathology 
report.  This was based on pathologic 
staging as per 2002 AJCC manual for 
staging of cancer15  For example, if the 
report only said IDC as the final diagnosis 
then this was listed as a stage I.  If the report 
described the specimen as IDC with 
ulceration, then this being a T4 descriptor 
was listed as a minimal stage 3B.  If the 
report stated “positive lymph nodes” this 
was listed as minimal stage 2A, etc.  This 
data likely reflects the difficulty with data 
collection rather than the actual stage at 
presentation as data from Africa usually 
describes advanced disease at presentation 
(5-9).  Eight reports could not be classified.  
Of 100 classified, 80 were Stage I, 18 were 
Stage IIA, 3 were Stage 3A, 3 were Stage 
3B, 1 was Stage 3C, and 5 were Stage 4.    
Benign breast disease was also reviewed for 
the same 1993 to August 2007 period. A 
total of  190 patients were identified.  Four 
cases had two pathological findings and thus 
192 lesions are reported.  The results are 
summarized in Table 2.  Most lesions were 
benign and nonproliferative lesions. One 
hundred ninety-two benign breast lesions, in 
190 patients, from Tenwek hospital during 
1993 to August 2007.  Four cases had two 
findings that were reported individually and 
involved fibrocystic changes or 
fibroadenoma in addition to the second 
lesion.  The “other” column involves 
lipomas, duct ectasia, lactational changes, 
etc.  
Fibroadenoma comprised the most common 
lesions (n=66) with a mean age of 23.85 
years (std 9.32) and 1.59% male incidence 
(Figure 2).  No lesions were described as 
having atypia or having florid proliferative 
changes.  A few proliferative lesions 
without atypia were noted such as 
papillomas and ductal hyperplasia.  These 
lesions have been described as having a 
relative risk of 1.88 for future breast 
cancer14.  
Unpublished data from this same institution 
also provides insight into the scope of breast 
disease in this area.  A review of all cancer 
pathology at Tenwek Hospital from January 
1, 1989 to August 31, 2007 was conducted 
by Parker and colleagues.  Breast cancer 
was the seventh most common cancer 
overall, fourth most common in women and 
twentieth most common in men for the same 
time period.      
  
Discussion  
The number of breast cancers diagnosed at 
our hospital in western Kenya has been on 
increase at Tenwek Hospital for the past 
fourteen years.  The diagnosis of breast 
cancer in men occurred at an older age 
compared with women.  The majority of 
breast cancer grades were high grade.  This 
observation remains true for pre-
menopausal women as well.  Benign breast 
disease was consistent with other data 
published in this country.  Our data suggests 
that breast cancer is of low occurrence in 
western Kenya and that it presents in a 
younger group of women with a biologically 
aggressive phenotype.  Given the nature of 
our review relying solely on pathologic 
diagnosis, it is difficult to derive incidence 
or prevalence data of breast cancer in this 
region.  There was also a higher than 
expected percentage of male breast cancer.  
As previously mentioned, this pattern is also 
seen with hereditary breast cancer.   
Male breast cancer in Nairobi, Kenya has 
previously been described occurring in 1.59-
3%9,14.  Similar data has been reported from 
elsewhere in East Africa.  Amir et al12` 
described fifty patients over a six-month 
period at a district hospital in Tanzania who 
were analyzed for type of breast cancer and 
stage.  Most had advanced breast cancer, 
with 76% having stage IIIB and 10% stage 
IV.  All of these patients were reported to 
have had IDC.  Most patients were pre-
menopausal, 90% being less than 50 years 
old.  Lacking from our data is information 
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of hormone receptor status and genetic data 
regarding oncogene expression and/or 
polymorphisms that may contribute to the 
disease burden in this area.  It is known that 
mutations in BRCA occur in higher 
prevalence in individuals of African descent 
(18%) compared with those of European 
descent (16%) when a large cohort of high-
risk individuals is screened13.  
In 2006, Nyagol and colleagues5 reviewed 
158 women in Kenya with breast cancer to 
evaluate prevalence of hormone receptors 
and Her-2/neu expression.  The trend noted 
with breast cancer in sub-Saharan Africa 
involves a younger onset compared with 
developed countries, a lower incidence 
overall, and a more advanced stage at 
presentation.  The majority of breast cancer 
was grade III, as was noted in our data, and 
the majority presented with advanced breast 
cancer (Stage III or greater).  Over 
expression of Her-2/neu was associated with 
high grade tumors.  Hormone receptor 
positive status was associated with both 
high grade and post-menopausal status.  Of 
note, 28% had all three negative ER, PR and 
Her-2/neu and 6% had all three positive.  
Seventeen had ER+, 35 had PR+, 32 had 
both ER and PR+.  At least one steroid 
hormone receptor was present in 53%.  
About 50% were premenopausal. Absent the 
receptor status data, the other features of 
this study from Kenya are similar to our 
data and it would be interesting to know if 
this population treated in Nairobi reflects 
the population found in rural western Kenya 
where our data was collected.  An earlier 
review examined breast cancers treated in 
Nairobi from the early 1980’s and noted a 
similar trend with 88% being IDC, 71% 
poorly differentiated and an increasing 
incidence from age 20 until menopause with 
a decline after menopause.  This incidence 
pattern is in contrast to the rise beyond 
menopause noted in North America and 
Europe6.  
Benign breast disease has previously been 
reported as series in Kenya with 650 cases 
from the early 1980’s.  Similar to our data, 
and others, fibroadenoma was the most 
common lesion with a peak incidence at 
around age 207.  
Many breast cancers in developing countries 
present with locally advanced disease.  
Optimally, adjuvant chemotherapy may 
improve the response to surgery as well as 
allow for conservation therapy.  The 
response to adjuvant therapy is also an 
important indicator of prognosis.  While 
multimodal therapy is recommended there 
are significant barriers to obtaining this in 
developing countries.  Alternatives to anti-
estrogen medical therapy should be 
explored such as oophorectomy 10.  Lack of 
multi-modality therapy for patients with 
breast cancer is a reality for most in Kenya.  
A retrospective review was carried out for a 
recent 11 year period in 374 patients treated 
for breast cancer at the national referral 
center in Nairobi, Kenya8.  During this time, 
only 22 received adjuvant chemotherapy, 21 
had chemotherapy for palliative purposes.  
Adjuvant radiation therapy was received by 
46 and 53 had it for palliative purposes.  
Hormonal therapy (tamoxifen) was given to 
126 during this time.  Interestingly, only one 
man was included in this group of 374 
reviewed.  This is in contrast to the 11% 
noted in our rural review and this differs 
from the recently reported Nairobi Cancer 
Registry listing male breast disease at 3%9.  
Less than 10% of patients had Stage I 
disease, with 60% having at least Stage III 
disease.  Even with this large percentage of 
advanced breast disease, only 6% received 
adjuvant chemotherapy.  Follow-up for this 
group was very limited.  The reasons for 
this sub-optimal approach as given by the 
authors include prohibitive cost and 
physician awareness.  Additional reasons 
cited as presenting difficulty for multimodal 
therapy for breast cancer in Africa include 
lack of advanced pathology testing (e.g. 
hormone receptor status)16.  While 
tamoxifen is generally available, including 
at our rural hospital in western Kenya, 
without receptor status knowledge empiric 
therapy for all increases the cost burden as 
well as presumably raising the risk-benefit 
ratio with the added risk of thromboembolic 
events and cervical cancer.  It is not known 
what percentage of our patients received any 
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therapy beyond surgery.  Tamoxifen is 
available locally but not the pathology 
resources to determine hormone receptor 
status.     
Support for breast cancer patients is limited 
in developing countries.  In other regions, 
there may be a belief that breast cancer is 
the result of a curse or supernatural 
influence; therefore, it may only be treated 
with supernatural therapy16.  The stigma 
associated with such a malady may fuel 
secrecy among families and reluctance to 
seek medical attention until it is far 
advanced.  Lack of awareness and social 
taboos about the disease often impede the 
process of screening, treatment and support 
for the patient11.  Increased public awareness 
and screening programs are indicated for 
those areas that breast cancer occurs at a 
younger age and more aggressively.  
An additional feature of our data is that it 
emphasizes the global difference in breast 
cancer between Africans and persons of 
African descent compared with other races.  
A significant percentage of women with 
breast cancer in our series were pre-
menopausal and had high grade carcinoma.   
This issue has been documented more 
extensively in North America.  Newman 
reviewed this topic and reported an earlier 
onset and more aggressive phenotype in 
African-American women compared with 
Caucasian-American women3.  There is a 
lower incidence in African-American 
women overall, but a higher incidence for 
American women younger than 45 
years3. African-American women are more 
likely to be diagnosed with node positive, 
high grade, hormone receptor negative 
breast cancer compared with Caucasian-
American women.  Incidence of breast 
cancer in North America and Europe is 
estimated to be approx 100 per 100,000 
persons compared with the estimated lower 
incidence in western Africa of 20 per 
100,000 3,17. Similar data has been found 
with comparison of women from the United 
States only.  
A lower incidence in women of African 
descent from SEER (Surveillance, 
Epidemiology and End-Results) data 
showing an age-adjusted breast cancer 
incidence of 119 per 100,000 women 
compared with 141 per 100,000 Caucasian-
American women1.  The reason for lower 
incidence of breast cancer in Africa is 
unclear and may be related to lifestyle 
protective factors such as reproductive 
patterns. It should be noted that there is 
paradoxically a briefly increased risk of 
breast cancer in the post-partum period, but 
the influence of this phenomenon is 
unclear.   An interesting relationship noted 
by Newman involves the similarity in 
features between African-American and 
African women with breast cancer in that 
both groups tend to have an earlier onset, 
higher grade, more advanced disease at 
presentation and lower survival rates. 3  The 
reason for higher mortality from breast 
cancer in African-Americans is unclear but 
has been speculated to be related to 
socioeconomic status and medical co 
morbidities.  A recent review examined this 
issue and when accounting for these factors, 
the mortality risk for African-Americans 
was 28% higher1. An increased 
understanding of breast cancer among 
Africans is likely to benefit both groups.    
A review by Chen and colleagues18, 
examined breast cancer histology comparing 
US women of African descent with non-
African descendents.  They found African-
American women had a higher chance of 
having high-grade tumours, more necrosis 
and oestrogen receptor positive tumours.  
After controlling for socioeconomic status, 
height and weight, and use of tobacco and 
alcohol, reproductive history and access to 
health care – these differences 
remained18. They quote data of African-
Americans having an overall lower 5-year 
survival from breast cancer of 62% 
compared with 79% with whites21.  Newman 
et al19 reviewed the SEER database of 
patients seen in Detroit from 1990 to 1999 
with breast cancer.   
African-American women were found to 
have larger primary tumors, more medullary 
cancer, more Oestrogen and Progesterone 
hormone receptor negative tumors, and 
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poorer survival.  Mean survival for African-
Americans was 45.2 months compared with 
49.9 months.  The authors note that 
hormone receptor negative and high-grade 
medullary tumors are features seen with 
hereditary breast cancer and this was also 
noted in AA women in this review20. Social 
factors and access to medical care cannot 
adequately explain these differences.  Data 
from western countries where breast cancer 
natural history, survival, histology and 
receptor status has been more extensively 
documented show a clear racial difference 
in breast cancer tumour biology. These data 
suggest a difference in tumour biology of 
patients with breast cancer of African 
descent.  
Further investigation should emphasize 
characterizing risk factors and 
epidemiologic data to better understand the 
breast cancer burden in East Africa.  
Relating this data to study of tumour 
biology including hormone receptor, her-
2/neu status and histology should provide 
focus for further improvements in breast 
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